Experiment 1142694
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | ISSEL,BF: ELNHORN,LH: COMIS,RL: LAWSON,RD: BAKER,LH: HARVEY,HA: LANOTTI,VA: WAMPLER,GL: DANIELS,JR: ANDERSON,PN: HONG,WK: RENTSCHLER,RE: PIKLER,GM: MAROUN,JA: WERNZ,JC: ROSENBAUM,PF:. (1985). MULTICENTER PHASE II TRIAL OF ETOPOSIDE IN REFRACTORY SMALL CELL LUNG CANCER.. 69(1) |
| Amount utilized | |
| Compound isolated | |
| Disease | IN THIS MULTICENTER PHASE II TRIAL ON ONE HUNDRED AND SIXTEEN PATIENTS WITH REFRACTORY SMALL CELL LUNG CANCER. PATIENTS WERE TREATED INITIALLY ON DAYS 1-5 IV WITH COURSES REPEATING EVERY 3-4 WEEKS WITH 80MG/SQ.M. SUBSEGUENT COURSES WERE DE-ESCALATED BY 20% TO MAINTAIN BLOOD COUNT. THIRTY ONE PATIENTS RECEIVE THE DRUG BY IV THE FIRST DAY AND THEN ORALLY DAYS 2-5 AT 160MG/SQ.M. THERE WAS ONE COMPLETE REMISSION AND 10 PARTIAL REMISSIONS ON THE REGULAR IV SCHEDULE. ON THE IV-PO SCHEDULE, 4 PATIENTS ACHIEVED PARTIAL REMISSION. LEUKOPENIA WAS SEEN IN ALL PATIENTS AND THROMBOCYTOPENIA WAS SEEN IN 25%. FIVE PATIENTS IN THE IV GROUP AND 1 PATIENT IN THE IV-PO GROUP DIED OF GRANULOCYTOPENIA RELATED SEPSIS. NON-HEMATOLOGICAL TOXICITY INCLUDED NAUSEA AND VOMITING WHICH OCCURRED IN 23% OF THE PATIENTS AND ANOREXIA WHICH OCCURRED IN 10%. |
| Dose amount | 80.0 MG |
| Number | 1 |
| Qualitative result | EQUIVOCAL |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |